FDA-CERSI Collaborative Research: FDA **Impacts on Advancing Public Health** CERSI

September 13, 2019 | Impacts Presentations 10:45 AM – 12:00 PM I Mix and Mingle 12:00 – 12:45 PM

> White Oak, Great Room Building 31 **Adobe Remote Access :**

Comparing qualitative and quantitative approaches to eliciting patient preferences: A case study on innovative upper limb prostheses.

John Bridges, Johns Hopkins University CERSI

1. Characterization and Analysis of High Incidence of Potentially Unsafe Prescribing of Some Extended-Release (ER) Opioid Analgesics Using Natural Language Processing (NLP) of Electronic Health Record (EHR) Clinical Notes.

Molly Jeffery, PhD, Yale-Mayo CERSI


Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients.

James Polli, PhD, University of Maryland CERSI

Use of Natural Language Processing/Machine Learning to Analyze Medication Error Reports and Improve the Quality of Data Submitted to the FDA Adverse Event Reporting System (FAERS).

Russ Altman, MD, PhD, UCSF-Stanford CERSI

FOR QUESTIONS or REASONABLE ACCOMODATIONS: Please contact Audrey. Thomas@fda.hhs.gov or Interpreting.services@oc.fda.gov



Jo Wyeth, CDER





Heather Benz, CDRH